Hikma Invests $1 Billion to Expand US Generics Manufacturing
Hikma Pharmaceuticals USA announces $1 billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines.
This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma’s well-established domestic capabilities to develop, produce, and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide.
Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance, and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines.
America Leans on Hikma represents the Company’s latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey.
"We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines.”
Bill Larkins, President, Hikma Injectables added, “Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients.”
